Abstract
B cell-depleting therapies such as ocrelizumab (OCR) are highly effective in people with multiple sclerosis (MS). Especially at treatment start and initial infusion, infusion-related reactions (IRR) are a common adverse event. The relevance of acute changes of cell-depleting therapies on peripheral immune compartments and routine lab testing is important for clinical practice. We systematically analyzed routine blood parameters, detailed blood immunophenotyping and serum cytokine profiles in 45 MS patients starting on OCR. Blood samples were collected before and after corticosteroid premedication and directly after each OCR infusion of the first three ocrelizumab infusions. Blood B cells were rapidly depleted and accompanied only by a mild cytokine release at the first OCR infusion. Cytokine release was not significantly detectable from a third application in line with decreasing IRRs. B cell depletion was accompanied by short-lived changes in other immune cell populations in number, activation and cytokine secretion after each OCR infusion. Standard lab parameters did not show any clinically relevant changes. Our data demonstrate only mild changes during the first OCR infusion, which are not present any more during long-term treatment.
Subject
Inorganic Chemistry,Organic Chemistry,Physical and Theoretical Chemistry,Computer Science Applications,Spectroscopy,Molecular Biology,General Medicine,Catalysis
Reference27 articles.
1. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis;Hauser;N. Engl. J. Med.,2017
2. No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a;Havrdová;Mult. Scler. J. Exp. Transl. Clin.,2018
3. Ocrelizumab in Primary Progressive and Relapsing Multiple Sclerosis;Hauser;N. Engl. J. Med.,2017
4. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis;Montalban;N. Engl. J. Med.,2017
5. The potential role for ocrelizumab in the treatment of multiple sclerosis: Current evidence and future prospects;Sorensen;Ther. Adv. Neurol. Disord.,2016
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献